[From nobody Thu Mar 15 13:40:56 2012 Received: from fox.mur.at (fox.mur.at [193.171.120.7]) by hornet.mur.at (Postfix) with ESMTP id B69761810E; Wed, 3 Dec 2003 02:32:57 +0100 (CET) Received: from dsl-200-67-204-52.prod-infinitum.com.mx (dsl-200-67-204-52.prod-infinitum.com.mx [200.67.204.52]) by fox.mur.at (Postfix) with SMTP id 9F22C3B1A9; Wed, 3 Dec 2003 02:32:49 +0100 (CET) Message-ID: <1q5we6po$3eo$n3f11x23bg2yh@0pm6s.b.qo> From: "Alexandria Blanchard" <k936plhsxq@yahoo.com> Reply-To: "Alexandria Blanchard" <k936plhsxq@yahoo.com> To: tini@mur.at Cc: <comunity@mur.at> Subject: US STOCK MARKET - HTDS Medical Research---CANCER Trials.....adam Date: Wed, 03 Dec 2003 07:21:52 +0600 MIME-Version: 1.0 Content-Type: multipart/alternative; boundary=".B6_34F_..E..B9FC8..B85" --.B6_34F_..E..B9FC8..B85 Content-Type: text/plain; Content-Transfer-Encoding: quoted-printable US Stock Market - Stock Profile of the Week Symbol: HTDS Market: PK Sector: MEDICAL RESEARCH BARCHART Rates HTDS an 80% BUY - http://quotes.barchart.com/texpert.asp?sy= m=3DHTDS Before we begin our profile we have very exciting, breaking news... Tubercin Passes Toxicity Trials - Ready To Proceed To Live Cancer Trials BREAKING NEWS - DELRAY BEACH, Fla.--(BUSINESS WIRE)--Hard to Treat Disease= s Incorporated (Pink Sheets:HTDS) announces that Tubercin=AE has passed th= e toxicity tests required to proceed to the live cancer trials. Testing Tu= bercin=AE on live Melanoma, Lung and Breast cancer cells will begin immedi= ately. The President and CEO, Mr. Colm J. King, met with the spokesperson= of the medical group at their offices in Oklahoma City. Mr. King was advi= sed that the tests were conducted under strict FDA (Federal Drug Administr= ation) guidelines. Full test results will be available at the corporate of= fices as soon as the reports and findings are printed. "These are the most promising results to date regarding Tubercin=AE and we= 're looking forward to additional positive results in the near future," st= ated Mr. King. "These tests prove that Tubercin=AE is non-toxic and is the= first step on the way to human clinical trials as well as the first posit= ive breakthrough conducted in the United States with an independent medica= l group for Tubercin=AE." Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporate= d ("HTTD") holds the international marketing rights, except South Korea, t= o Tubercin=AE, a patented immunostimulant developed for combating Cancer u= nder medical patent (US Patent 6,274,356). The unique properties unlike ot= her cancer products are clearly stated in the abstract summary of the pate= nt... "A carbohydrate complex, which is a mixture of low molecular-weight = polysaccharides of an arabinomannan structure extracted from Mycobacterium= tuberculosis, is highly effective in treating various cancer patients wit= hout incurring any adverse side effects." STOCK PROFILE OF THE WEEK HTDS is now at an emerging and potentially explosive stage. As stated in = their press release, Tubercin is now ready to proceed (after tests conduct= ed under strict FDA guidelines) to human clinical trials. While they have= jumped one very big hurdle, they are still in the early stages of develop= ment and now is a great time for investors to take heed. TUBERCIN Over the past ten years, epoch making anticancer agents have continuously = been introduced, but the mortality of cancer patients have been rising in = the U.S. and the European countries not to mention Japan and Korea. The de= cisive measure to cope with cancer is surgery. When the cancer cells spread throughout the body instead of remaining on t= he original spot, the treatment should take into consideration chemotherap= y, radiation therapy and immunotherapy. The drawback of such therapies, ho= wever, is they incur damages not only on cancer cells, but also on the nor= mal cells. Chemotherapy and radiation therapy are not suitable for application on wea= kened patients, especially those above 70. Historically, various forms of = immunotherapy have been performed, falling short of therapeutic expectatio= n. When Bacille calmetteguerin is used as an active no-specific immunother= apeutic agent, however, the patient's prognosis turns better through a sim= ulative action on immune system of the cancer case. Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from= microbacterium tuberculosis to be used as immunostimulant. This was meant= to activate the T-lymphocyte of the cancer patient to produce lymphokine.= This process strengthened and promoted immuno surveillance activities in = deficient state and alleviated the pain and prolonged the life of cancer p= atients. Of late the pharmaceutical industry in advanced countries started to put o= n the market so called cancer vaccines (active specific immunotherapy). Th= e vaccines, bacterial extracts, as adjuvants, with autologous and or allog= enic cancer cells to generate antibodies to cancer cells, facilitating the= killer T-cells to recognize and destroy cancer cells. The laboratory work to modify autologous or allogenic cancer cells are not= ordinary and simple. When our lab work augments the active specific immun= otherapeutic agents, the Tubercin will be one of the best adjuvants. Meanw= hile, the main point of AIDS is its virus killing T-cells and Tubercin hel= ps maintain healthy T-cells. Consequently, we focus our effort on the appl= ication of Tubercin to AIDS. TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimula= nt, TUBERCIN strengthens the human body's own immune system and assists th= e body in seeking out and combating cancer cells. HTTD is potentially able= to develop TUBERCIN into a low-cost product to treat cancer patients on a= n international scale. Salient treatment, through the administration of TU= BERCIN, could positively affect thousands of lives in North America. In ad= dition, Europe and Asia have millions of lives at risk each year because o= f viral diseases such as cancer. TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been ad= ministered to human patients in stages three and four of terminal cancer. = There have been no indications of any adverse side effects in human trials= There has been encouraging results of patients with TUBERCIN in the last= fourteen years. Various forms of cancer were involved and many of the pat= ients survived. A review of clinical studies indicate TUBERCIN has no side effects and cou= ld possibly be administered in conjunction with other such modalities for = the treatment of cancer without any adverse effects. The scientific presum= ption would be the distinct possibility of a strengthened immunity system = and the administration of treatment such as chemotherapy at the later stag= es of tumor growth would not be impeded by the weakened condition of the t= erminal cancer patient. To this end the Company has been assisted by outsi= de consultants reviewing the research data and human trials involving TUBE= RCIN to see specifically whereby incidents of dual treatment produced favo= rable results in terms of moving toward indication of prolongation of the = life of the cancer patient. There is recognition that morphine is an trusted pain killer, but in total= ity it cannot be said that it has no side effects. In the maintaining of p= atient care, there is the strong possibility that TUBERCIN could be also c= onsidered as a candidate for a pain management. The Company's scientists d= escribe TUBERCIN as having the high propensity of deadening the nerve endi= ngs in specific areas of the body where cancer has caused erosion and cons= equently much pain. PATENTS Presently, HTTD has the patent rights for Korea, Japan and the United Stat= es. The Korean patent was issued on October 29, 1998 (Registration No. 173= 362). The Japanese patent was issued on June 12, 1998 (Registration No. 27= 90447). The United States patent was issued on August 14, 2001 (Registrati= on No.6,274,356). Currently, patents are pending for Canada and Europe (th= e United Kingdom, France, Germany, Italy and Spain). CANCER IN OUR TIME In the 20th century, the number of cancer patients has been on the increas= e. Although many anti-cancer agents were developed and an enormous study o= n its essence continued, the mortality by cancer still is increasing. Mank= ind may be chronically threatened with cancer in the 21st century. Nine mi= llion new case of cancer occur annually and five million people die from b= reast cancer, reports the World Health Organization. Dramatic increases in= life expectancy and change in lifestyle are estimated to increase the num= ber of new cancer cases to 20 million annually by 2020 and cancer deaths t= o more than 10 million. About 552,200 Americans - more than 1,500 people a day - are excepted to d= ie of cancer this year. In the United States, one of every four deaths is = attributed to cancer. Cancer is the second-leading cause of death in the U= nited States. Exceeded only by heart disease. About 5 million lives have b= een lost to cancer since 1990 and about 13 million new cases have been dia= gnosed. In 2000, more then 1.2 million new cancer cases are expected to be= diagnosed. The number of cancer cases will continue to grow, spurred by t= he aging population. By 2009, this patient group could total 8.4 million. = In 1997, about 6.3 million people worldwide died from some form of cancer,= and most major international cancer agencies expect this number to double= by 2022. Please note that HTDS had absolutley nothing to do with this report and is= not a participant in any way. No more advertisements: http://doubleopt.biz/optout.html Stock Market Today is an independent research firm. This report is based o= n Stock Market Today's independent analysis but also relies on information= supplied by sources believed to be reliable. This report may not be the o= pinion of HTDS management. Stock Market Today has also been retained to re= search and issue reports on HTDS. Stock Market Today may from time to time= purchase or sell HTDS common shares in the open market without notice. Th= e information contained in this report shall not constitute, an offer to s= ell or solicitation of any offer to purchase any security. It is intended = for information only. Some statements may contain so-called "forward-looki= ng statements". Many factors could cause actual results to differ. Investo= rs should consult with their Investment Advisor concerning HTDS. Copyright= 2003 =A9 Stock Market Today Ltd. All Rights Reserved. This newsletter was= distributed by MMS, Inc. MMS was paid eight hundred and fifty thousand sh= ares HTDS stock to distribute this report. MMS is not affiiated with Stock= Market Today and is not responsible for newsletter content. oxoss wsz hp rjywcpzaacy w x jo v yesxl w xaeq --.B6_34F_..E..B9FC8..B85-- ]